# A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD

> **NCT06488313** · PHASE2 · RECRUITING · sponsor: **Arcturus Therapeutics, Inc.** · enrollment: 9 (estimated)

## Conditions studied

- OTC Deficiency
- Ornithine Transcarbamylase Deficiency
- OTCD

## Interventions

- **BIOLOGICAL:** ARCT-810

## Key facts

- **NCT ID:** NCT06488313
- **Lead sponsor:** Arcturus Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-11-04
- **Primary completion:** 2026-06-01
- **Final completion:** 2026-09-01
- **Target enrollment:** 9 (ESTIMATED)
- **Last updated:** 2025-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06488313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06488313, "A Study to Evaluate the Pharmacodynamics and Safety of ARCT-810 in Participants With OTCD". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06488313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*